Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Recruitment underway for phase II trial for breast cancer antibody therapy
August 25th, 2005
A targeted antibody therapy for breast cancer appears to be well tolerated and clinically active in a phase I trial. According to a study from Germany, "Targeted therapies against tumor biological properties are an essential part of individualized therapy concepts in breast cancer. Next to risk-adapted strategies using conventional chemo-and/or endocrine therapies, antibody therapy has become an additional option." "The humanized monoclonal antibody trastuzumab (Herceptin) is the first novel targeted therapy approved for routine clinical application in advanced breast cancer. Patients with HER2/neu protein over expression as assessed by...
Source: Women's Health Weekly (2005-08-25)
|
